Evidence map›Paper›PMID 33743371›Full record

ReviewJournal of infection and public health2021

Combating COVID-19: The role of drug repurposing and medicinal plants.

Shah A Khan, K Al-Balushi

Open access · goldAbstract readReview
In one paragraph

Review in Journal of infection and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Foods (Basel, Switzerland) · 2024
    Review
  3. Review
  4. Phytomedicines explored underSouth African journal of botany : official journal of the South African Association of Botanists = Suid-Afrikaanse tydskrif vir plantkunde : amptelike tydskrif van die Suid-Afrikaanse Genootskap van Plantkundiges · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Molecular and structural insights of β-boswellic acid and glycyrrhizic acid as potent SARS-CoV-2 Envelope protein inhibitors.Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2022
    Article
  11. Molecules (Basel, Switzerland) · 2022
    Review
  12. Article
  13. Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2022
    Article
  14. Article
  15. Article
  16. Biomolecules · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. The find of COVID-19 vaccine: Challenges and opportunities.Journal of infection and public health · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Shah A KhanCollege of Pharmacy, National University of Science and Technology, PO Box 620, PC 130, Muscat, Oman. Electronic address: shahalam@nu.edu.om.
K Al-BalushiCollege of Pharmacy, National University of Science and Technology, PO Box 620, PC 130, Muscat, Oman.
Muscat College · OMNational University of Science and Technology · ZW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA novel corona virus-2 disease has spread to 213 countries and territories across the globe. The corona pandemic has claimed more than 548,934 deaths worldwide till the evening of 8th of July 2020 and the number of confirmed cases is increasing at an alarming rate. Therefore, there is an urgent need to find a treatment or a vaccine for COVID-19 at the earliest. The aim of this mini-review is to give an overview of identified repurposed anti-COVID-19 drugs which are currently under clinical trials.

methodsA thorough literature survey was done to retrieve relevant information using various web based search engines such as Google, Google scholar, and various other electronic research databases such as PubMed, Medline, MeSh etc. The findings of the recently published articles, clinical trials, COVID-19 update by World Health Organization etc., and the opinion of the authors is summarized in this brief review. The antiviral medicinal plants were identified based on their use in Chinese/Indian indigenous systems of medicine, traditional use, published scientific phytochemical studies and/or their effectiveness against upper respiratory infections, severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).

resultsThe disease is just over six months old and effective prophylactic or therapeutic agents are yet to be developed for COVID-19. Thus, in the absence of an effective therapy, scientific community has rationally considered the drug repurposing approach for the development of anti COVID-19 drugs. Various studies and clinical trials involving antimalarial drugs, anti-HIV drugs, anti-hepatitis drugs, anti-parasitic drug, anti-inflammatory drugs, the combination of antimalarial and macrolide antibiotic and few other molecules identified through drug repurposing are currently underway to combat COVID-19. Due emphasis is also given to develop novel corona vaccines for the prophylaxis and to identify drugs for adjunct/supportive therapy. Several medicinal plants along with their major phytochemicals exhibiting antiviral activity are identified for further exploration. It is anticipated that these natural products might also play an important role in combating COVID-19.

conclusionsUse of drug repurposing strategy to develop anti COVID-19 drugs and exploring antiviral medicinal plants as adjunct or supportive therapy appears to be a viable option. Therefore, it is the need of the hour to work in parallel on different strategies such as genetic engineering, in silico approach, herbal remedies and drug repositioning to achieve the common goal of finding a safe and effective treatment for COVID-19 at the earliest.

Indexed as

COVID-19 Drug TreatmentDrug RepositioningPlants, MedicinalAntiviral AgentsHumansPhytotherapyAntiviral AgentsCorona virusCOVID-19Drug repurposingMedicinal plantsPandemic

Identifiers

PMID33743371
PMCPMC7590838
OpenAlexW3095467329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.